Plus: FDA approves Freestyle Libre 2; metformin adherence; HbA1c variability & mortality
Can't see the images? View as webpage.
Facebook
Twitter
LinkedIn
To ensure that you never miss an issue, please whitelist us.

June 16, 2020 : DCMS #506

TOP STORIES - Diabetes News & Research


A New Diabetes Drug Class

Patient-Specific Factors Affect Metformin Adherence

Comparing Long-Term HbA1C Variability with All-Cause Mortality in the ACCORD Trial
Letter from the Editor

We have spent a lot of time talking about TIR (Time in Range) for diabetes patients, but most of it is focused on type 1 patients. There is even more info on the long-term benefits of increased TIR being presented at this week's ADA Virtual Scientific sessions.

But what about this idea for patients with type 2 diabetes? Can they benefit from less variability from month to month, and from office visit to office visit? This week our intern, Stephen Rubano, PharmD. Candidate, USF Taneja College of Pharmacy, looked back at the ACCORD trial and found there is a direct connection between Long Term A1c Stability and better outcomes.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief


Doctor's Option lab test products include rapid tests and CLIA certified fingerstick lab tests.

Rapid tests offer immediate test results to provide doctors with point of care test results in as little as 90 seconds.

Fingerstick lab tests provide CLIA certified lab accurate results. Each fingerstick lab test collection kit comes with a prepaid postage return envelope and everything you need to obtain and collect your fingerstick blood sample in a 510K FDA approved device.

Fingerstick lab tests are great for people who want to monitor their blood sugar, cholesterol, lipids and other important bio-markers at home or on the go.

Visit Doctor's Option

Newsflash: FDA Approves FreeStyle® Libre 2


Abbott announced on June 15th that the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2 integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes.

A dose of humor...

Cartoon
 

TOP STORIES - Diabetes News and Research

A New Diabetes Drug Class
Imeglimin, a new, first-in-class blood-glucose-lowering agent, proves to be safe and efficient as monotherapy and adjunctive therapy to lower A1C in patients with type 2 diabetes.
READ MORE
Patient-Specific Factors Affect Metformin Adherence
A large UK study investigates which patients may be likely to discontinue metformin therapy. 
READ MORE
Comparing Long-Term HbA1C Variability with All-Cause Mortality in the ACCORD Trial
Study shows that visit-to-visit HbA1C variability can have significant effects on the prognosis for patients living with diabetes.
READ MORE

MOST POPULAR ARTICLES OF THE MONTH


#1 Why CGM?

#2 Did You Know? Metformin, along with dozens of drugs, may have promise against COVID-19

#3 5 Key Exercises for People with Diabetes
 About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com
Facebook
Twitter
LinkedIn
©2020 HIPER, LLC. All rights reserved.

This email was sent by eHealthcare Solutions on behalf of:
Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States

DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe